HMC
Harvard Management Company Portfolio holdings
AUM
$1.44B
This Quarter Return
+14.54%
1 Year Return
+33.17%
3 Year Return
+230.83%
5 Year Return
+163.57%
10 Year Return
+194.2%
AUM
$1.74B
AUM Growth
+$1.74B
(-2.9%)
Cap. Flow
-$96.8M
Cap. Flow
% of AUM
-5.57%
Top 10 Holdings %
Top 10 Hldgs %
81.62%
Holding
43
New
5
Increased
3
Reduced
12
Closed
5
Top Buys
| 1 |
Apple
AAPL
|
$333M |
| 2 |
Recursion Pharmaceuticals
RXRX
|
$55.1M |
| 3 |
DaVita
DVA
|
$49.2M |
| 4 |
Meta Platforms (Facebook)
META
|
$38.2M |
| 5 |
Affirm
AFRM
|
$32.2M |
Top Sells
| 1 |
Intercontinental Exchange
ICE
|
$163M |
| 2 |
Adobe
ADBE
|
$155M |
| 3 |
Royalty Pharma
RPRX
|
$146M |
| 4 |
Microsoft
MSFT
|
$61.7M |
| 5 |
Palo Alto Networks
PANW
|
$35.2M |
Sector Composition
| 1 | Healthcare | 38.04% |
| 2 | Technology | 27.47% |
| 3 | Consumer Discretionary | 12.12% |
| 4 | Communication Services | 10.39% |
| 5 | Financials | 4.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Apple
AAPL
$3.45T
| $333M | 19.19% | +2,434,903 | New | +$333M |
|
|
2
Royalty Pharma
RPRX
$15.6B
| $293M | 16.85% | 7,142,856 -3,571,428 | -33% | -$146M |
|
3
Light & Wonder
LNW
$7.76B
| $207M | 11.94% | 2,678,571 | – | – |
|
|
4
Meta Platforms (Facebook)
META
$1.86T
| $181M | 10.39% | 519,456 +109,761 | +27% | +$38.2M |
|
|
5
Palo Alto Networks
PANW
$127B
| $91.3M | 5.25% | 245,943 -94,957 | -28% | -$35.2M |
|
6
AbCellera Biologics
ABCL
$1.25B
| $90.3M | 5.2% | 4,105,095 | – | – |
|
|
7
Intercontinental Exchange
ICE
$101B
| $81.7M | 4.7% | 688,549 -1,373,895 | -67% | -$163M |
|
|
8
Recursion Pharmaceuticals
RXRX
$2.04B
| $55.1M | 3.17% | +1,509,254 | New | +$55.1M |
|
|
9
DaVita
DVA
$9.85B
| $49.2M | 2.83% | +408,912 | New | +$49.2M |
|
10
10x Genomics
TXG
$1.74B
| $36.5M | 2.1% | 186,143 +96,667 | +108% | +$18.9M |
|
11
Invesco QQQ Trust
QQQ
$364B
| $36.2M | 2.08% | 102,222 -5,722 | -5% | -$2.03M |
|
|
12
Affirm
AFRM
$28.8B
| $32.2M | 1.85% | +477,421 | New | +$32.2M |
|
13
iShares Core S&P 500 ETF
IVV
$662B
| $28.1M | 1.62% | 65,342 -174 | -0.3% | -$74.8K |
|
14
PureCycle Technologies
PCT
$2.57B
| $25.3M | 1.46% | 1,069,600 -206,667 | -16% | -$4.89M |
|
15
Revolution Medicines
RVMD
$7.1B
| $21.3M | 1.22% | 670,382 | – | – |
|
16
Unity
U
$16.7B
| $20.5M | 1.18% | 186,396 | – | – |
|
17
Relay Therapeutics
RLAY
$619M
| $19.8M | 1.14% | 541,124 | – | – |
|
18
Pliant Therapeutics
PLRX
$101M
| $16.4M | 0.94% | 562,379 | – | – |
|
19
SPDR Gold Trust
GLD
$107B
| $15.2M | 0.88% | 91,955 -4,707 | -5% | -$780K |
|
20
Praxis Precision Medicines
PRAX
$958M
| $14.2M | 0.82% | 778,517 | – | – |
|
21
Generation Bio
GBIO
$40.4M
| $13.8M | 0.79% | 512,349 | – | – |
|
|
KNTE
22
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $11.6M | 0.67% | 498,001 | – | – |
|
23
Sana Biotechnology
SANA
$777M
| $9.22M | 0.53% | 468,749 | – | – |
|
24
Vanguard FTSE Developed Markets ETF
VEA
$171B
| $8.38M | 0.48% | 162,699 -13,238 | -8% | -$682K |
|
25
Nurix Therapeutics
NRIX
$714M
| $8.35M | 0.48% | 314,762 | – | – |
|